This source used for this article is a comprehensive digital repository that documents more than 760 anecdotal accounts and case reports regarding the use of repurposed anti-parasitic medications, specifically fenbendazole, ivermectin, and mebendazole, in the treatment of various cancers. Compiled as a “September 2026 Update” by the platform OneDayMD, the text serves as a grassroots evidence base for patients and clinicians to explore non-traditional protocols, particularly when conventional therapies have failed. The structure is organized alphabetically by cancer type, ranging from common diagnoses like breast and prostate cancer to aggressive stage IV conditions and rare sarcomas. Beyond individual success stories, the text emphasizes a paradigm shift in medical research, advocating for the “right to try” and the value of real-world patient data (N=1) amid the high costs and logistical delays of traditional randomized controlled trials. Ultimately, the collection seeks to provide accessible, transparent information and a sense of community for those navigating advanced illness while maintaining a cautious stance that these accounts generate hypotheses rather than definitive medical proof.
A small sample (below) of the compiled sources that make up an extensive repository of documented case reports and patient testimonials detailing off-label experiences with repurposed antiparasitic agents—primarily fenbendazole, mebendazole, and ivermectin—across a wide array of malignancies. These compilations function as hypothesis-generating registries, bridging raw anecdotal accounts and formal clinical research.
1. Scope & Landmark Case Models
The Joe Tippens Protocol: A central catalyst for public interest involved Joe Tippens, who was diagnosed in 2016 with terminal, metastatic non-small-cell lung cancer (NSCLC). After self-administering veterinary fenbendazole alongside bioavailable curcumin and CBD oil, follow-up PET scans demonstrated complete metabolic clearance of all tumor sites; as of 2026, he remains cancer-free.
Real-World Patient Registries: Ongoing retrospective compilations (such as those published by Dr. William Makis and independent research teams) document high-dose ivermectin (typically 1.0–2.0 mg/kg/day) combined with mebendazole or fenbendazole. In an observational cohort study published in Anticancer Research (Hulscher et al., 2026) evaluating 122 patients who completed a 6-month follow-up on compounded ivermectin (25 mg) and mebendazole (250 mg), 84.4% reported clinical benefit (defined as no evidence of disease, tumor shrinkage, or disease stabilization).
2. Clinical Trends Across Specific Cancer Types
A. Brain Cancer & High-Grade Gliomas (135+ Cases)
Individual Case Reports: In a compilation of 38 individually documented intracranial tumor cases (including glioblastoma, medulloblastoma, and DIPG), 97% reported stable disease, partial regression, or complete response. Mebendazole and ivermectin are favored in neuro-oncology because of their high lipophilicity and ability to penetrate the blood-brain barrier.
The METRICS Cohort Study: In a retrospective cohort of 95 glioblastoma patients, adding a 4-drug adjunctive metabolic protocol—mebendazole (100 mg/day), atorvastatin, metformin, and doxycycline—to standard radiation and temozolomide extended median overall survival from 15 months to 27 months compared to historical controls.
B. Breast Cancer (130+ Cases)
Metastatic & Subtype Responses: Reports encompass aggressive subtypes including Triple-Negative Breast Cancer (TNBC), ER+/PR+, and HER2+ cases with widespread bone, liver, lung, and brain/leptomeningeal metastases.
Pathological & Molecular Remissions: Documented outcomes include complete pathological responses (pCR) before surgery in locally advanced TNBC, total clearance of circulating tumor DNA (ctDNA) on SIGNATERA/Guardant liquid biopsies, and long-term disease-free survival exceeding 2.5 years in stage IV bone-metastatic disease.
C. Lymphoma & Leukemia (43 Cases)
Hematologic Malignancies: The case series describes radiographic remissions in Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Mantle Cell Lymphoma, and leukemias (AML/CLL).
Notable Outcomes: Reported cases include a 40-year-old patient with a 9 cm DLBCL mass who achieved a complete metabolic response on R-CHOP paired with ivermectin and fenbendazole, as well as an 83-year-old with stage IVa DLBCL who declined chemotherapy and demonstrated progressive, durable disease regression on fenbendazole monotherapy.
D. Gastrointestinal, Hepatic, & Rare Cancers
Liver & Bile Duct (Cholangiocarcinoma): Serial imaging in intrahepatic cholangiocarcinoma demonstrates extensive central tumor necrosis (photopenia on PET scans) and volumetric shrinkage, allowing previously unresectable patients to qualify for liver transplantation.
Pediatric & Adult Sarcomas: Successful cases describe complete radiographic resolution in radiation-induced sarcomas (e.g., a 12-year-old boy reaching “No Evidence of Disease”) and leiomyosarcomas when combining mebendazole, ivermectin, and standard radiation.
3. Methodological Limitations & Causal Ambiguity
While these reports provide a compelling real-world signal, researchers emphasize several critical caveats:
Treatment Synergy vs. Standalone Efficacy: Over 70–80% of reported success stories involve patients taking repurposed antiparasitics concurrently with standard-of-care chemotherapy, radiation, targeted therapy (e.g., Enhertu, Kisqali), or immunotherapy. The primary biological mechanism often points toward chemosensitization—where antiparasitic agents enhance cancer cell susceptibility and mitigate standard treatment side effects—rather than acting purely as standalone cures.
Selection & Survivorship Bias: Unverified social media accounts inherently capture positive outcomes while omitting treatment failures, dropouts, or disease progression.
Need for Prospective Controlled Trials: Because anecdotal series lack defined denominators and control groups, researchers consistently conclude that these findings justify formal scientific investigation but cannot replace randomized controlled trials (RCTs) or standard-of-care oncology guidelines.
Important Disclaimers
This content is for educational purposes only and does not constitute medical advice. Ivermectin, fenbendazole, and mebendazole are used off-label for cancer and are not FDA-approved for this purpose. Always consult a knowledgeable physician you trust to manage your health. Individual results may vary. Do not self-medicate without proper bloodwork and medical monitoring — misuse can cause serious side effects and drug interactions.
These agents are, at most, complementary and are not intended to replace conventional, evidence-based cancer treatment such as chemotherapy, radiotherapy, immunotherapy, targeted therapy, or hormone therapy. Discuss any off-label use with and have it supervised by a qualified physician as part of an individualized treatment plan.
Non-Hodgkin lymphoma, Hodgkin lymphoma, and acute leukemias are potentially life-threatening and can progress rapidly without appropriate treatment. Do not delay or forgo standard, evidence-based cancer therapy. Consider any complementary or off-label treatment only in consultation with a qualified oncologist, to complement—not replace—recommended conventional care.
Fenbendazole, Ivermectin and Mebendazole for Cancer: Case Series of 760+ Case Reports (September 2026 Update)
The Medical Advisor
Conventional medicine saves lives, but innovative and integrative approaches can extend and enhance them
https://www.onedaymd.com/2024/02/fenbendazole-cancer-success-stories.html